Side effects of Sinopharm Vaccine experienced by healthcare professionals of Holy Family Hospital, Rawalpindi, Pakistan
Objectives: To determine the gender and age based disparities in side effects among healthcare workers in response to COVID-19 (Sinopharm) vaccination
Subjects & Methods: Total 216 healthcare workers were vaccinated against COVID-19 by administering Sinopharm vaccine during February and March 2021 at Infectious Diseases Department of Holy Family Hospital Rawalpindi were enrolled in the study through consecutive sampling. Data for this cross-sectional descriptive study was gathered pertinent to age, gender and side effects of Sinopharm vaccination. The information regarding vaccination side effects was inquired through telephonic calls. Data was analyzed by means of SPSS version 25.0.
Results: Mean age of healthcare workers in our study was 35.7 ± 9.5 years. Most (54.6%) of them were females. About 79.2% of health professionals were 21-40 years old. Side effects after first dose of Sinopharm vaccine were experienced by 46.3% males and 42.4% females. About 45.2% and 42.3% males and females respectively overlooked the second jab adversity. Greater proportion (43.6%) complained of vaccine related side effects after the second dose than 37.5% subjects who noted side effects after the first dose of vaccine. Bodyaches, injection site pain, headache and fever were established as the commonest post-vaccination side effects.
Conclusion: Side effects resulting from Sinopharm vaccine among our healthcare personnel were minimal. Fortunately none of them complained of serious aftereffects. Despite the COVID vaccination, our healthcare workers should strictly adhere to COVID SOPs amidst pandemic in order to avoid catastrophe in future.
2. UK Research and Innovation. Global Challenges Research Fund. Available at: https://www.ukri.org/research/global-challenges-research-fund/.
3. Das L, Meghana A, Paul P, Ghosh S. Are we ready for COVID-19 vaccines? – A general side effects overview. CMRO 2021; 4(2): 830-841. DOI: https://doi.org/10.15520/jcmro.v4i02.398.
4. World Health Organization. COVID-19 Vaccines. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines.
5. NCOC Government of Pakistan. COVID Vaccination. https://ncoc.gov.pk/covid-vaccination-en.php.
6. J. Corum, S. Wee, C. Zimmer, Coronavirus vaccine tracker. NY Times (2021). https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html. Accessed 10 April 2021.
7. J Kennedy. Vaccine hesitancy: A growing concern. Paediatr Drugs 2020; 22: 105-111.
8. Johns Hopkins Bloomberg School of Public Health. Side effects and COVID-19 vaccines: What to expect. https://www.jhsph.edu/covid-19/articles/side-effects-and-covid-19-vaccines-what-to-expect.html.
9. Pakistan struggles to contain third COVID-19 wave. https://www.voanews.com/covid-19-pandemic/pakistan-struggles-contain-third-covid-19-wave.
10. Malik A, Malik J, Ishaq U. Acceptance of COVID-19 vaccine in Pakistan among healthcare workers. medRxiv 2021. DOI: https://doi.org/10.1101/2021.02.23.21252271.
11. Call for resuming healthcare workers’ registration for COVID-19 vaccination. The News April 21, 2021. https://www.thenews.com.pk/print/822425-call-for-resuming-health-workers-registration-for-covid-19-vaccination.
12. World Health Organization. Side effects of COVID-19 vaccines. https://www.who.int/news-room/feature-stories/detail/side-effects-of-covid-19-vaccines.
13. Flaxman S, Mishra S, Gandy A, et al. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. Nature 2020; 584: 257–61.
14. Sanche S, Lin YT, Xu C, Romero-Severson E, Hengartner N, Ke R. High contagiousness and rapid spread of severe acute respiratory syndrome coronavirus 2. Emerg Infect Dis 2020; 26: 1470–77.
15. WHO. Draft landscape of COVID-19 candidate vaccines. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.
16. Mild side effects of COVID-19 vaccines are normal: experts. https://www.thenews.com.pk/print/785753-mild-side-effects-of-covid-19-vaccines-are-normal-experts.
17. Sinopharm - Beijng Institute of Biological Products. http://sinopharm.com/en/s/1395-4173-38862.html
18. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N Engl J Med. 2020; 383: 2603-2615.
19. Goepfert PA, Fu B, Chabanon AL, Bonaparte MI, David MJ, Essink BJ, et al. Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomized, placebo-controlled, phase 1-2, dose ranging study. The Lancet Infectious Diseases 2021: 1-14. https://doi.org/10.1016/S1473-3099(21)00147-X.
20. Remmel A. COVID vaccines and safety: what the research says. Nature 2021; 590: 538-540. https://www.nature.com/articles/d41586-021-00290-x.
21. Akau K. Sex and gender and COVID-19 vaccine side effects. Yale School of Medicine. April 5, 2021. https://medicine.yale.edu/news-article/31448/.
22. Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1/2, single-blind, randomised controlled trial. The Lancet 2020; 396(10249): 467–478. DOI: 10.1016/S0140-6736(20)31604-4.
23. Kritz F. Study: Women have more pronounced COVID-19 vaccine side effects than men. https://www.verywellhealth.com/study-women-have-more-pronounced-covid-19-vaccine-side-effects-than-men-5116362.
24. Bar-Zeev N, Moss W. Encouraging results from phase 1/2 COVID-19 vaccine trials. The Lancet 2020; 396(10249): 448–449. DOI: 10.1016/S0140-6736(20)31611-1.
25. Crouch M. COVID-19 vaccine side effects are stronger in women. 31 March 2021. https://feeds.aarp.org/health/conditions-treatments/info-2021/women-covid-vaccine-side-effects.html?_amp=true.
26. Bendix A. The COVID-19 vaccine side effects you can expect based on your age, sex and dose. https://www.businessinsider.com/coronavirus-moderna-pfizer-vaccine-side-effects-age-sex-dose-2021-3.
27. Yoysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AXD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa and the UK. Lancet 2021; 397: 99–111. https://doi.org/10.1016/ S0140-6736(20)32661-1.
Copyright (c) 2021 Rizwana Shahid, Muhammad Umar, Muhammad Mujeeb Khan, Shazia Zeb, Ayesha Nadar, Sheema Afzal
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
All research articles published in the Journal of Rawalpindi Medical College (JRMC) are fully open access: immediately freely available to read, download, and share. Copyrights of all articles published in JRMC are retained by the authors. First publication rights are granted to JRMC. The journal/publisher is not responsible for subsequent uses of the work.
All articles are published under the Creative Commons Attribution (CC BY-SA 4.0) license.